Literature DB >> 21086194

Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Seok Jin Kim1, Won Seog Kim.   

Abstract

Extranodal NK/T cell lymphoma predominantly presents as a localized disease in the upper aerodigestive tract from the nasal cavity to the hypopharynx. Because radiotherapy has better outcomes than chemotherapy with reduced locoregional failure, it should be considered the preferred first-line therapy. However, the addition of chemotherapy is appropriate as part of the initial treatment because of the frequent systemic progression or relapse after radiotherapy. At present, the combination of radiotherapy and chemotherapy can be considered an effective treatment option, and the promising results of recent prospective studies with concurrent chemoradiotherapy support this treatment strategy. In contrast, intensive chemotherapy should be considered as initial treatment for patients with tumors in non-upper-aerodigestive-tract sites, such as skin or intestine because they usually progress to systemic disease. Likewise, for patients with poor prognostic factors, such as a high NK lymphoma prognostic index, autologous stem cell transplantation during remission and additional treatments with central nervous system prophylaxis may be beneficial. However, the precise role of these treatments needs to be clarified further by prospective clinical trials. Thus, a prospective study is warranted to explore a risk-adapted treatment strategy of applying initial chemoradiotherapy and additional consolidation treatments.

Entities:  

Mesh:

Year:  2010        PMID: 21086194     DOI: 10.1007/s12185-010-0720-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  45 in total

1.  Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital.

Authors:  I Cuadra-Garcia; G M Proulx; C L Wu; C C Wang; B Z Pilch; N L Harris; J A Ferry
Journal:  Am J Surg Pathol       Date:  1999-11       Impact factor: 6.394

Review 2.  Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies.

Authors:  Tae Min Kim; Dae Seog Heo
Journal:  Cancer Sci       Date:  2009-08-19       Impact factor: 6.716

3.  Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification.

Authors:  Koh-ichi Sakata; Nobukazu Fuwa; Takeshi Kodaira; Kazunori Aratani; Hikaru Ikeda; Masaru Takagi; Masamichi Nishio; Masaaki Satoh; Shigeo Nakamura; Hidetoshi Satoh; Masato Hareyama
Journal:  Radiother Oncol       Date:  2006-04-27       Impact factor: 6.280

4.  The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma.

Authors:  Se-Hoon Lee; Yong Chan Ahn; Won Seog Kim; Young H Ko; Kihyun Kim; Keunchil Park
Journal:  Haematologica       Date:  2006-02-17       Impact factor: 9.941

5.  First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.

Authors:  Keun-Wook Lee; Tak Yun; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Sung-Soo Yoon; Dae Seog Heo; Yung-Jue Bang; Seonyang Park; Byoung Kook Kim; Noe Kyeong Kim
Journal:  Leuk Lymphoma       Date:  2006-07

6.  CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?

Authors:  W S Kim; S Y Song; Y C Ahn; Y H Ko; C H Baek; D Y Kim; S S Yoon; H G Lee; W K Kang; H J Lee; C H Park; K Park
Journal:  Ann Oncol       Date:  2001-03       Impact factor: 32.976

7.  In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A.

Authors:  M Uno; J Tsuchiyama; A Moriwaki; T Noguchi; K Mizoguchi; T Ogino; T Yoshino; S Okada; M Harada
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

Review 8.  Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.

Authors:  Ritsuro Suzuki; Kengo Takeuchi; Koichi Ohshima; Shigeo Nakamura
Journal:  Hematol Oncol       Date:  2008-06       Impact factor: 5.271

9.  Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.

Authors:  Soon Thye Lim; Siew Wan Hee; Richard Quek; Lay Cheng Lim; Swee Peng Yap; Er-Li Loong; Ivy Sng; Leonard Hwan-Cheong Tan; Mei-Kim Ang; Joanne Ngeow; Chee-Kian Tham; Lynette Ngo; Min Han Tan; Miriam Tao
Journal:  Eur J Haematol       Date:  2007-11-20       Impact factor: 2.997

10.  L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.

Authors:  Weiben Yong; Wen Zheng; Jun Zhu; Yuntao Zhang; Xiaopei Wang; Yan Xie; Ningjing Lin; Bo Xu; Aiping Lu; Jiyou Li
Journal:  Ann Hematol       Date:  2008-12-24       Impact factor: 3.673

View more
  18 in total

1.  Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.

Authors:  Y Q Wang; Y Yang; H Y Zhuo; L Q Zou; Y Jiang; M Jiang
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

2.  High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.

Authors:  Hao Ding; Jun Chang; Li-Gen Liu; Dong Hu; Wen-Hao Zhang; Yun Yan; Li-Yuan Ma; Zhi-Chao Li; Yu-Jie Ma; Si-Guo Hao; Rong Tao
Journal:  Int J Hematol       Date:  2015-05-22       Impact factor: 2.490

3.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

4.  Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.

Authors:  Paola Ghione; Shunan Qi; Brandon S Imber; Venkatraman Seshan; Alison Moskowitz; Natasha Galasso; Matthew Lunning; David Straus; Craig Sauter; Parastoo Dahi; Ahmet Dogan; Joachim Yahalom; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2020-08-26

Review 5.  NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm.

Authors:  Ritsuro Suzuki
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

6.  Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group.

Authors:  E Tse; T S Y Chan; L-P Koh; W-J Chng; W-S Kim; T Tang; S-T Lim; A K W Lie; Y-L Kwong
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

Review 7.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

8.  Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group.

Authors:  Seok Jin Kim; Hyun Ae Jung; Shih-Sung Chuang; Huangming Hong; Cheng-Cheng Guo; Junning Cao; Xiao-Nan Hong; Ritsuro Suzuki; Hye Jin Kang; Jong Ho Won; Wee-Joo Chng; Yok-Lam Kwong; Cheolwon Suh; Yu-Qin Song; Jun Zhu; Kevin Tay; Soon Thye Lim; Junji Suzumiya; Tong-Yu Lin; Won Seog Kim
Journal:  J Hematol Oncol       Date:  2013-11-16       Impact factor: 17.388

9.  Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.

Authors:  Jing-Hua Wang; Hua Wang; Yan-Jun Wang; Zhong-Jun Xia; Hui-Qiang Huang; Wen-Qi Jiang; Yue Lu
Journal:  Oncotarget       Date:  2016-06-07

10.  Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.

Authors:  Li Zhang; Ming Jiang; Li Xie; Hong Zhang; Yu Jiang; Qun-pei Yang; Wei-ping Liu; Wen-yan Zhang; Hong-yu Zhuo; Ping Li; Nian-yong Chen; Sha Zhao; Feng Wang; Li-qun Zou
Journal:  Cancer Med       Date:  2015-12-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.